Friday, December 09, 2011 by Angela Kean
Resonance Health (ASX: RHT) is moving to protect the intellectual property associated with its diagnostic test for the assessment of fatty liver, HepaFat Scan, through the lodgement of a Provisional Patent Application.
The company has also registered the HepaFat Scan trademark and, importantly, begun discussions with interested parties on its potential use and licence.
Results of a clinical study conducted earlier in the year demonstrate that the MRI-based diagnostic product can accurately assess the severity of fatty liver disease, replacing the need for an invasive liver biopsy.
According to Resonance, nearly one in three Americans have fatty liver, and non-alcoholic fatty liver disease is the most common liver disease in the U.S. and Europe.
An accurate diagnosis of early stage fatty liver disease provides a better outcome for patients, to address the condition before the onset of liver damage.
Meanwhile, Resonance has also recorded substantial growth in the sales volumes of its non-invasive, MRI-based service for the measurement of liver iron overload, FerriScan, in the 2012 financial year.
From July to November 2011 there has been a 30% month-on-month increase in the numbers of FerriScans sold, compared to the same period in 2010.
Resonance announced earlier this week it has expanded the distribution of FerriScan into the Middle East with the appointment of Gulf Drug Establishment as a distributor.
Gulf Drug Establishment will distribute the FerriScan service in the United Arab Emirates, Saudi Arabia and Egypt where there is a high number of patients with iron overload caused by regular blood transfusions to treat an underlying condition.
FerriScan is currently available through over 120 centres in more than 20 countries. Resonance witnessed strong growth in new FerriScan users in Brazil, Japan, Italy and China in 2010-11.
No comments:
Post a Comment